Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$88.29 USD
+0.21 (0.24%)
Updated Oct 30, 2024 04:00 PM ET
Pre-Market: $88.12 -0.17 (-0.19%) 9:08 AM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$88.29 USD
+0.21 (0.24%)
Updated Oct 30, 2024 04:00 PM ET
Pre-Market: $88.12 -0.17 (-0.19%) 9:08 AM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Mallinckrodt's Stannsoporfin Gets Complete Response Letter
by Zacks Equity Research
Mallinckrodt's (MNK) pipeline candidate, Stannsoporfin gets a Complete Response Letter from the FDA.
Don't Worry About An Inverted Yield Curve...YET
by John Blank
The U.S. economy should remain out of recession until 2020.
Alnylam Completes Enrollment in Phase III Givosiran Study
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) completes enrollment in the phase III ENVISION study ahead of schedule of its pipeline candidate, givosiran.
Pacira (PCRX) Rides High on Robust Exparel Performance
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.
Allergan Falls on FDA's Rejection of Uterine Fibroids Drug
by Zacks Equity Research
FDA rejects Allergan's (AGN) new drug application for Esmya for the treatment of abnormal uterine bleeding in women with uterine fibroids, citing safety issues.
Infinity Focuses on Developing IPI-549 for Solid Tumors
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) aims at developing its pipeline candidate, IPI-549.
Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC
by Zacks Equity Research
AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.
Alexion's BLA for ALXN1210 Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.
China Biologic Products (CBPO) Looks Good: Stock Adds 8.7% in Session
by Zacks Equity Research
China Biologic Products (CBPO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Amazon, Petroleo Brazileiro, Gilead Sciences and KLA-Tencor
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Petroleo Brazileiro, Gilead Sciences and KLA-Tencor
Bristol-Myers' Opdivo Gets FDA Nod for Small Cell Lung Cancer
by Zacks Equity Research
Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cancer indication, which shall further expand the addressable patient population of the drug.
Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin
by Zacks Equity Research
Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.
Time for Jackson Hole: Global Week Ahead
by John Blank
The world???s central bankers are going to be in Jackson Hole, Wyoming speaking to Jerome Powell and the rest of the Fed contingent. Mr. Powell himself will speak Friday morning.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Regeneron, Teva Announce Positive Data on Osteoarthritis Drug
by Zacks Equity Research
Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.
Zacks Value Trader Highlights: Sony, Carrizo Oil & Gas, Intel, United Rentals and Gilead
by Zacks Equity Research
Zacks Value Trader Highlights: Sony, Carrizo Oil & Gas, Intel, United Rentals and Gilead
Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study
by Zacks Equity Research
Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.
Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study
by Zacks Equity Research
Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.
Lessons from a Legendary Value Investor
by Tracey Ryniec
Value investors are rare. Find out what it takes to be one and how to find value stocks from one of the greats.
Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
by Zacks Equity Research
Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years
Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit
by Zacks Equity Research
Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.
Shire, Shionogi File NDA for Intuniv for Adults in Japan
by Zacks Equity Research
Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.
Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech
by Zacks Equity Research
Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.
Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic
by Zacks Equity Research
Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.